These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30658902)

  • 1. Intravenous iron induced severe hypophophatemia in a gastric bypass patient.
    Gómez Rodríguez S; Castro Ramos JC; Abreu Padín C; Gómez Peralta F
    Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):340-342. PubMed ID: 30658902
    [No Abstract]   [Full Text] [Related]  

  • 2. Case report: A rare cause of severe hypophosphatemia.
    Román-Gimeno S; Ortez-Toro JJ; Peteiro-Miranda CM; Sanz-Martín B; Urdaniz-Borque R
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):125-126. PubMed ID: 32409006
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
    Barea Mendoza JA; Gredilla Zubiría I; González Olmedo J; Mateo Alvarez S
    Med Clin (Barc); 2014 Sep; 143(6):284-5. PubMed ID: 24461741
    [No Abstract]   [Full Text] [Related]  

  • 4. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.
    Mani LY; Nseir G; Venetz JP; Pascual M
    Transplantation; 2010 Oct; 90(7):804-5. PubMed ID: 20881582
    [No Abstract]   [Full Text] [Related]  

  • 6. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 7. Parenteral iron therapy and phosphorus homeostasis: A review.
    Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA
    Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophosphatemia in children treated with ferric carboxymaltose.
    Posod A; Schaefer B; Mueller T; Zoller H; Kiechl-Kohlendorfer U
    Acta Paediatr; 2020 Jul; 109(7):1491-1492. PubMed ID: 31955454
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
    Amarnani R; Travis S; Javaid MK
    Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323
    [No Abstract]   [Full Text] [Related]  

  • 11. Blood and Bone Loser.
    Schaefer B; Glodny B; Zoller H
    Gastroenterology; 2017 May; 152(6):e5-e6. PubMed ID: 28384445
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
    Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypophosphataemia following ferric carboxymaltose and ferric derisomaltose: case closed, but questions remain.
    Chauhan A; Lucas S; Garg M
    Gut; 2024 May; 73(6):1039. PubMed ID: 37193585
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient.
    Fierz YC; Kenmeni R; Gonthier A; Lier F; Pralong F; Coti Bertrand P
    Eur J Clin Nutr; 2014 Apr; 68(4):531-3. PubMed ID: 24569537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy.
    Sangrós Sahún MJ; Goñi Gironés E; Camarero Salazar A; Estébanez Estébanez C; Lozano Martínez ME
    Rev Esp Med Nucl Imagen Mol; 2016; 35(6):391-393. PubMed ID: 27246291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphataemia Following Ferric Carboxymaltose Infusion.
    McGrath KH; Khoo PWR
    J Paediatr Child Health; 2021 Sep; 57(9):1546. PubMed ID: 34291512
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.
    Bager P; Hvas CL; Dahlerup JF
    Br J Clin Pharmacol; 2017 May; 83(5):1118-1125. PubMed ID: 27859495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypophosphatemia associated with use of intravenous ferric carboxymaltose].
    Proaño Fierro ME; Rodríguez Cañete BL; Sánchez Sobrino P; Rego Iraeta AL
    Nutr Hosp; 2023 Dec; 40(6):1301-1304. PubMed ID: 37929853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.